New Therapy Update Aprocitentan an Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension

Authors

Michael Airo, New York Medical College
WIlliam H. Frishman, New York Medical College
Wilbert S. Aronow, New York Medical CollegeFollow

Author Type(s)

Student, Faculty

DOI

10.1097/CRD.0000000000000591

Journal Title

Cardiology in Review

First Page

114

Last Page

119

Document Type

Article

Publication Date

3-1-2025

Department

Medicine

Keywords

endothelin, endothelin receptor antagonist, hypertension

Disciplines

Medicine and Health Sciences

Abstract

Resistant hypertension (RH) is the state of uncontrolled blood pressure in the face of ostensibly optimal pharmacological intervention. It accounts for roughly one in six cases of hypertension, and is associated with more severe morbidity and mortality outcomes than is non-RH. The prevalence of RH implies a currently unmanaged pathology, which may involve the potent vasoconstrictor endothelin. Several endothelin receptor antagonists are currently marketed for pulmonary arterial hypertension, but none so far has been marketed for RH. Aprocitentan is currently in development, an endothelin receptor antagonist that effectively produces clinically significant and sustained decreases in systolic and diastolic blood pressure in the setting of RH.

Recommended Citation

Airo, M., Frishman, W., & Aronow, W. (2025). New Therapy Update Aprocitentan an Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension. Cardiology in Review, 33 (2), 114-119. https://doi.org/10.1097/CRD.0000000000000591